--- canonical_url: https://www.stockexpertai.com/earnings/syk last_updated: 2026-05-09T17:48:43.447Z --- # Stryker Corporation (SYK) Q4 FY2026 Earnings Preview > This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-09T17:48:42.873Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $285.47 (▼ -2.98%) | fmp:quote | | Market Cap | $109.3B | fmp:profile | | 52w range | $284.95 – $404.87 | fmp:quote | | Earnings | Thu 30 Jul | fmp:earnings-history | | EPS estimate | $3.47 (+11% YoY) | fmp:earnings-estimate | | Revenue estimate | $6.6B | fmp:earnings-estimate | | Beat streak | 0/4 | fmp:earnings-history | | Rating | B (overall 3/5) | fmp:ratings | | Analyst median target | $394 (+38.0% upside) | fmp:price-target-consensus | | MoonshotScore | 50/100 | derived | | Council | 5/6 bullish | derived | | Munger verdict | Undervalued | derived | ## Stryker Corporation — Q4 FY2026 Expectations Q4 consensus: revenue $6.6B^{[FMP est]}, EPS $3.47^{[FMP est]}. 0 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** B · **Stance:** BUY · **Council:** 5/6 · **Moonshot:** 50 = MoonshotScore 50^{[9-pillar formula]} + Council 5/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (6 metrics) ### 1. Procedural Volumes And Capex Stryker is seeing solid procedural volumes supported by favorable demographics and the continued adoption of robotic-assisted surgery, as well as a steady hospital CapEx environment. > "Procedural volumes were solid, supported by favorable demographics and the continued adoption of robotic-assisted surgery. The hospital CapEx environment also remains steady, and our capital order book remains elevated as we enter the remainder of the year." > — Jason Beach, Vice President of Finance and Investor Relations, Risk Indicator · Q1 FY2026 ### 2. Fy26 Guidance Maintained Stryker is maintaining its full year guidance for both revenue and earnings per share despite disruptions from the cyber incident. > "Despite the disruption we experienced this quarter, we are maintaining our full year guidance." > — Preston Wells, CFO, Expectation / Guide · Q1 FY2026 ### 3. Mako Installations Q1 Stryker delivered its best ever Q1 for Mako installations both in the U.S. and internationally, with high and increasing utilization rates across the globe. > "Additionally, we delivered our best ever Q1 for Mako installations both in the U.S. and internationally, with high and increasing utilization rates across the globe." > — Jason Beach, Vice President of Finance and Investor Relations, Investor Focus · Q1 FY2026 ### 4. Cyber Incident Impact The cyber incident meaningfully impacted Stryker's first quarter results, but the company expects normalization over the course of the year and is maintaining its full year guidance. > "While our growth this quarter was meaningfully impacted by the cyber incident, we remain encouraged by the solid fundamentals in the markets we serve and remain well positioned within them. As a result, we are maintaining our full year guidance and look forward to another year of healthy performance in 2026." > — Kevin Lobo, Chair and Executive Officer, Investor Focus · Q1 FY2026 ### 5. Amplitude Vascular Systems Acquisition Stryker announced the agreement to acquire Amplitude Vascular Systems to help expand treatment options for peripheral vascular customers and is also a step toward expanding our presence in the broader cardiovascular space. > "On the M&A front, we recently announced the agreement to acquire Amplitude Vascular Systems that we expect to close in the second quarter. The acquisition of AVS will help expand treatment options for our peripheral vascular customers and is also a step toward expanding our presence in the broader cardiovascular space." > — Kevin Lobo, Chair and Executive Officer, Investor Focus · Q1 FY2026 ### 6. Ortho Tech Business Stryker established its new Ortho Tech business by combining the Mako and Enabling Technologies with the Orthopaedic Instruments portfolio to simplify the customer experience, accelerate innovation and increase our speed to market. > "Also, at the beginning of Q1, we established our new Ortho Tech business by combining the Mako and Enabling Technologies with the Orthopaedic Instruments portfolio from our Instruments business to simplify the customer experience, accelerate innovation and increase our speed to market." > — Kevin Lobo, Chair and Executive Officer, Investor Focus · Q1 FY2026 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 0.0 | weak | Q1 vs Q2: growth negative (-0.0%, contraction) | | Gross Margin | 6.0 | medium | Q1: high margin (63.3%) | | Operating Leverage | 2.0 | weak | op margin healthy (15.5%) | | Cash Runway | 10.0 | strong | FCF very strong ($0.4B, 2.5× CapEx) | | R&D Intensity | 5.0 | medium | average R&D (6.4%) | | Price Momentum | 4.0 | medium | RSI 23.1 oversold, 50d below | | News Sentiment | 8.0 | strong | strong buy consensus (76%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +38.0% | | Ken Griffin | bear | flow · 50d MA below | | Jim Simons | bull | quant · RSI 23 | | Klarman | bull | value · target upside +38.0% | | Buffett | bull | quality · ROE score 4/5 | | Munger | bull | valuation · target upside +38.0% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Undervalued - **Financial Health:** Moderate - **Margin of Safety:** Strong - **Interest Coverage:** Adequate - **ROIC vs WACC:** Healthy **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 23.1 — oversold (RSI 23.1) — tepki alımı potansiyeli - **50d MA:** $336 — hisse %15.0 altında — kısa vadeli direnç - **200d MA:** $362 — hisse %21.2 altında — uzun vadeli baskı - **Volume (10d):** -25% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q2 FY25 | $3.13 | $3.07 | BEAT | -3.8% | | Q3 FY25 | $3.19 | $3.13 | BEAT | -3.5% | | Q4 FY25 | $4.47 | $4.40 | BEAT | +4.3% | | Q1 FY26 | $2.60 | $2.98 | +-12.8% EPS | -6.5% | Q1 (April 30, 2026): EPS $2.60 vs $2.98 est^[FMP], +-12.8% beat. D+1 movement: -6.5%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q4 EPS > $3.47 + CapEx discipline** Threshold: EPS > $3.47^{[FMP est]}. Target: Break above median target $394^{[FMP target]}; high target $465^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $3.47 + CapEx < $166.0M** Threshold: EPS ≈ $3.47^{[FMP est]}, Q4 CapEx < $166.0M^[FMP]. Target: Consolidation in the band between current $285^[FMP] and median $394^[FMP]. ### Scenario C · Miss **EPS < $3.37 or CapEx ≥ $166.0M** Threshold: EPS < $3.37^{[FMP est×0.97]}. Target: Current $285 below SMA200 $362^[FMP], if rejection continues, $308^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q1: EPS $2.60 vs $2.98 beat^[FMP], stock -6.5% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q1 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26 ### CapEx shock Q1 CapEx $166.0M^{[FMP cashflow]}. Q1 op margin 15.5%^{[FMP op margin]} — this level in Q4 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $394 (+38.0% upside vs current $285) - **High / Low:** $465 / $315 - **Buy / Hold / Sell:** 22 / 7 / 0 - **Analyst count:** 11 (last quarter), 80 all-time ## Additional Transcript Insights ### 1. fy26_guidance_maintained **Claim:** Stryker is maintaining its full year guidance for both revenue and earnings per share despite disruptions from the cyber incident. **Evidence (transcript):** "Despite the disruption we experienced this quarter, we are maintaining our full year guidance." **Numbers:** — ### 2. mako_installations_q1 **Claim:** Stryker delivered its best ever Q1 for Mako installations both in the U.S. and internationally, with high and increasing utilization rates across the globe. **Evidence (transcript):** "Additionally, we delivered our best ever Q1 for Mako installations both in the U.S. and internationally, with high and increasing utilization rates across the globe." **Numbers:** — ### 3. ortho_tech_business **Claim:** Stryker established its new Ortho Tech business by combining the Mako and Enabling Technologies with the Orthopaedic Instruments portfolio to simplify the customer experience, accelerate innovation and increase our speed to market. **Evidence (transcript):** "Also, at the beginning of Q1, we established our new Ortho Tech business by combining the Mako and Enabling Technologies with the Orthopaedic Instruments portfolio from our Instruments business to simplify the customer experience, accelerate innovation and increase our speed to market." **Numbers:** — ### 4. amplitude_vascular_systems_acquisition **Claim:** Stryker announced the agreement to acquire Amplitude Vascular Systems to help expand treatment options for peripheral vascular customers and is also a step toward expanding our presence in the broader cardiovascular space. **Evidence (transcript):** "On the M&A front, we recently announced the agreement to acquire Amplitude Vascular Systems that we expect to close in the second quarter. The acquisition of AVS will help expand treatment options for our peripheral vascular customers and is also a step toward expanding our presence in the broader cardiovascular space." **Numbers:** — ### 5. cyber_incident_impact **Claim:** The cyber incident meaningfully impacted Stryker's first quarter results, but the company expects normalization over the course of the year and is maintaining its full year guidance. **Evidence (transcript):** "While our growth this quarter was meaningfully impacted by the cyber incident, we remain encouraged by the solid fundamentals in the markets we serve and remain well positioned within them. As a result, we are maintaining our full year guidance and look forward to another year of healthy performance in 2026." **Numbers:** 2026 ### 6. procedural_volumes_and_capex **Claim:** Stryker is seeing solid procedural volumes supported by favorable demographics and the continued adoption of robotic-assisted surgery, as well as a steady hospital CapEx environment. **Evidence (transcript):** "Procedural volumes were solid, supported by favorable demographics and the continued adoption of robotic-assisted surgery. The hospital CapEx environment also remains steady, and our capital order book remains elevated as we enter the remainder of the year." **Numbers:** — --- *Data source: FMP (live query, 2026-05-09), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*